Who are amorolfine 5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Voriconazole preemptive genotyping strategy, Topical Sertaconazole 2%, Nizoral®, Loceryl NL 12 weeks, Clotrimazole vaginal tablets+ Lactobacillus, Loceryl Nail Lacquer.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amorolfine-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

amorolfine 5% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

amorolfine 5% (amorolfine 5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal. Area: Dermatology.

phase 3 Antifungal Lanosterol 14α-demethylase Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

amorolfine 5% (amorolfine 5%) — Polichem S.A.. Amorolfine is an antifungal agent that inhibits the growth of fungi by interfering with the synthesis of ergosterol, an essential component of fungal cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
amorolfine 5% TARGET	amorolfine 5%	Polichem S.A.	phase 3	Antifungal	Lanosterol 14α-demethylase
Voriconazole preemptive genotyping strategy	Voriconazole preemptive genotyping strategy	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal with pharmacogenomic optimization	CYP2C19 enzyme (pharmacogenomic target); fungal lanosterol 14α-demethylase (therapeutic target)
Topical Sertaconazole 2%	Topical Sertaconazole 2%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Nizoral®	Nizoral®	Ache Laboratorios Farmaceuticos S.A.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Loceryl NL 12 weeks	Loceryl NL 12 weeks	Galderma R&D	marketed	Allylamine antifungal	Lanosterol 14α-demethylase (CYP51)
Clotrimazole vaginal tablets+ Lactobacillus	Clotrimazole vaginal tablets+ Lactobacillus	Peking University Shenzhen Hospital	marketed	Antifungal + probiotic combination	Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration
Loceryl Nail Lacquer	Loceryl Nail Lacquer	Galderma R&D	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal class)

Cidara Therapeutics Inc. · 1 drug in this class
Drugs for Neglected Diseases · 1 drug in this class
Fernanda P Silveira, MD, MS · 1 drug in this class
LI YAN · 1 drug in this class
Novartis · 1 drug in this class
Polichem S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amorolfine 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/amorolfine-5. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing